OBJECTIVE: The present study aimed to identify differentially expressed proteins employing a high resolution mass spectrometry (MS)-based proteomic analysis of endometrial cancer cells harvested using laser microdissection. METHODS: A differential MS-based proteomic analysis was conducted from discrete epithelial cell populations gathered by laser microdissection from 91 pathologically reviewed stage I endometrial cancer tissue samples (79 endometrioid and 12 serous) and 10 samples of normal endometrium from postmenopausal women. Hierarchical cluster analysis of protein abundance levels derived from a spectral count analysis revealed a number of proteins whose expression levels were common as well as unique to both histologic types. An independent set of endometrial cancer specimens from 394 patients were used to externally validate the differential expression of select proteins. RESULTS: 209 differentially expressed proteins were identified in a comparison of stage I endometrial cancers and normal post-menopausal endometrium controls (Q<0.005). A number of differentially abundant proteins in stage I endometrial cancer were identified and independently validated by western blot and tissue microarray analyses. Multiple proteins identified with elevated abundance in stage I endometrial cancer are functionally associated with inflammation (annexins) and oxidative processes (peroxiredoxins). PRDX1 and ANXA2 were both confirmed as being overexpressed in stage I cancer compared to normal endometrium by independent TMA (Q=0.008 and Q=0.00002 respectively). CONCLUSIONS: These data provide the basis for further investigation of previously unrecognized novel pathways involved in early stage endometrial carcinogenesis and provide possible targets for prevention strategies that are inclusive of both endometrioid and serous histologic subtypes. Published by Elsevier Inc.
OBJECTIVE: The present study aimed to identify differentially expressed proteins employing a high resolution mass spectrometry (MS)-based proteomic analysis of endometrial cancer cells harvested using laser microdissection. METHODS: A differential MS-based proteomic analysis was conducted from discrete epithelial cell populations gathered by laser microdissection from 91 pathologically reviewed stage I endometrial cancer tissue samples (79 endometrioid and 12 serous) and 10 samples of normal endometrium from postmenopausal women. Hierarchical cluster analysis of protein abundance levels derived from a spectral count analysis revealed a number of proteins whose expression levels were common as well as unique to both histologic types. An independent set of endometrial cancer specimens from 394 patients were used to externally validate the differential expression of select proteins. RESULTS: 209 differentially expressed proteins were identified in a comparison of stage I endometrial cancers and normal post-menopausal endometrium controls (Q<0.005). A number of differentially abundant proteins in stage I endometrial cancer were identified and independently validated by western blot and tissue microarray analyses. Multiple proteins identified with elevated abundance in stage I endometrial cancer are functionally associated with inflammation (annexins) and oxidative processes (peroxiredoxins). PRDX1 and ANXA2 were both confirmed as being overexpressed in stage I cancer compared to normal endometrium by independent TMA (Q=0.008 and Q=0.00002 respectively). CONCLUSIONS: These data provide the basis for further investigation of previously unrecognized novel pathways involved in early stage endometrial carcinogenesis and provide possible targets for prevention strategies that are inclusive of both endometrioid and serous histologic subtypes. Published by Elsevier Inc.
Authors: Leroi V DeSouza; Jörg Grigull; Shaun Ghanny; Valérie Dubé; Alexander D Romaschin; Terence J Colgan; K W Michael Siu Journal: Mol Cell Proteomics Date: 2007-03-19 Impact factor: 5.911
Authors: Andrey Kropotov; Vladimir Gogvadze; Oleg Shupliakov; Nikolay Tomilin; Vladimir B Serikov; Nikolai V Tomilin; Boris Zhivotovsky Journal: Exp Cell Res Date: 2006-05-17 Impact factor: 3.905
Authors: G Larry Maxwell; Chunqiao Tian; John Risinger; Carol L Brown; G Scott Rose; J Tate Thigpen; Gini F Fleming; Holly H Gallion; Wendy R Brewster Journal: Cancer Date: 2006-11-01 Impact factor: 6.860
Authors: Carsten Merkwirth; Sascha Dargazanli; Takashi Tatsuta; Stefan Geimer; Beatrix Löwer; F Thomas Wunderlich; Jürgen-Christoph von Kleist-Retzow; Ari Waisman; Benedikt Westermann; Thomas Langer Journal: Genes Dev Date: 2008-02-15 Impact factor: 11.361
Authors: Roger S Day; Kevin K McDade; Uma R Chandran; Alex Lisovich; Thomas P Conrads; Brian L Hood; V S Kumar Kolli; David Kirchner; Traci Litzi; G Larry Maxwell Journal: BMC Bioinformatics Date: 2011-05-27 Impact factor: 3.169
Authors: Ebony R Hoskins; Brian L Hood; Mai Sun; Thomas C Krivak; Robert P Edwards; Thomas P Conrads Journal: PLoS One Date: 2011-09-30 Impact factor: 3.240
Authors: H C Whitaker; D Patel; W J Howat; A Y Warren; J D Kay; T Sangan; J C Marioni; J Mitchell; S Aldridge; H J Luxton; C Massie; A G Lynch; D E Neal Journal: Br J Cancer Date: 2013-07-23 Impact factor: 7.640
Authors: Elena Martinez-Garcia; Antoine Lesur; Laura Devis; Alexandre Campos; Silvia Cabrera; Jan van Oostrum; Xavier Matias-Guiu; Antonio Gil-Moreno; Jaume Reventos; Eva Colas; Bruno Domon Journal: Oncotarget Date: 2016-08-16